<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Treatment of focal <z:hpo ids='HP_0002637'>cerebral ischemia</z:hpo> in the rat with intraperitoneal administration of <z:chebi fb="28" ids="17026">progesterone</z:chebi> dissolved in <z:chebi fb="0" ids="28262">dimethyl sulfoxide</z:chebi> (DMSO) has demonstrated therapeutic efficacy </plain></SENT>
<SENT sid="1" pm="."><plain>In the present study we test whether iv administration of water soluble <z:chebi fb="28" ids="17026">progesterone</z:chebi> 2 h after the <z:hpo ids='HP_0003674'>onset</z:hpo> of middle cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp> provides therapeutic benefit for the treatment of <z:hpo ids='HP_0001297'>stroke</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>In addition, we perform a battery of functional tests: rotarod, adhesive-backed somatosensory, and neurological score, as well as a dose-response study </plain></SENT>
<SENT sid="3" pm="."><plain>The data indicate that iv administration of <z:chebi fb="28" ids="17026">progesterone</z:chebi> at a dose of 8 mg/kg significantly reduces the volume of <z:e sem="disease" ids="C0007785" disease_type="Disease or Syndrome" abbrv="">cerebral infarction</z:e> and significantly improves outcome on the array of functional measures employed </plain></SENT>
<SENT sid="4" pm="."><plain>Treatment with 4 mg/kg or 32 mg/kg of <z:chebi fb="28" ids="17026">progesterone</z:chebi> failed to provide any therapeutic benefit </plain></SENT>
<SENT sid="5" pm="."><plain><z:chebi fb="28" ids="17026">Progesterone</z:chebi>, a non toxic, clinically employed, pluripotent therapeutic agent which targets both neuroprotective as well as neuroregenerative strategies, may have important therapeutic benefits for the treatment of <z:hpo ids='HP_0001297'>stroke</z:hpo> </plain></SENT>
</text></document>